OMass Therapeutics has secured £27.5m funding.
The investment round into the Oxford-based BioTech firm takes its total funding to £41.5m.
Investors include €20m from Syncona, €12.6m from Oxford Sciences Innovation and €600,000 from the University of Oxford.
OMass is using native mass spectrometry to design small molecule drugs to treat unspecified immunological and genetic disorders.
“Emerging biophysical technologies like native mass spectrometry can meaningfully improve drug discovery and impact global health outcomes,” Lachlan Mackinnon, Principal at Oxford Sciences Innovation, said.
Chief executive Ros Deegan joined the company from Bicycle Therapeutics last year.
She said the new investment into OMass comes “as we discover, develop and ultimately commercialise novel medicines to bring life-changing benefits to patients with immunological and genetic diseases”.